NCT00457444已完成1 期
ZU-SkinSIT-001 Single Center Phase I/IIa, Placebo Controlled, Randomized, Double Blind Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- efficacy
研究概览
简要总结
Primary Objective Comparison of the inhibition of the allergic response assessed by nasal provocation test after epicutanous pollen allergen administration and placebo epicutaneous administration.
Secondary Objectives Comparison of the efficacy of the placebo with that of the epicutanous pollen allergen administration evaluated by visual analog symptom scales (nasal itching, sneezing, rhinorrhea, conjunctival redness, and lacrimation, lung symptoms ), Comparison of the inhibition of the allergic response assessed by skin prick test after epicutanous pollen allergen administration and placebo epicutaneous administration.
- Trial with medicinal product
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •History of grass pollen allergic rhinitis
- •Male and female between 18 years to 65 years
- •Positive skin prick test to grass pollen
- •Positive nasal provocation test
排除标准
- •Atopic eczema in history or permanent
- •Perennial allergic rhinitis
- •Symptoms of infectious disease with rhinitis in between the last 2 weeks
- •Surgical intervention in between the last 30 days
- •Pregnancy or nursing
- •History of HIV or AIDS
- •Mastocytosis (cutaneous or systemic)
- •Significant cardiovascular disease
- •Hypertension (blood pressure > 160 / 95)
- •Significant pulmonary, renal and/or hepatic disease
- •Significant hematological disorder
- •Moderate or severe asthma
- •History of malignancy
- •History of neurological or psychatric disease
- •Autoimmune disease
- •Antihistamines with longed half-lives in the last week
- •Systemic or topical steroids for 5 days
- •Active infectious disease
- •Contraindicated medications: - immunosuppressive agents
- •Betablockers
- •ACE-inhibitors
- •Tricyclic antidepressants
- •Daily use of Beta-agonists or steroid inhalers
- •Participation in another clinical trial /study in between the last 60 days
- •Participation in another clinical trial / study at the moment
结局指标
主要结局
efficacy
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesSeasonal Allergic RhinitisNCT00883168Meda Pharmaceuticals1,791
已完成
不适用
Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic RhinitisSeasonal Allergic RhinitisNCT00334698Fraunhofer-Institute of Toxicology and Experimental Medicine51
已完成
4 期
Effects of Sublingual Immunotherapy on Grasspollen AllergyHayfeverNCT00150514Radboud University Medical Center38
已完成
3 期
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesSeasonal Allergic RhinitisNCT00740792Meda Pharmaceuticals776
已完成
1 期
Study of a Topical Nasal Spray to Ease the Symptoms of HayfeverRhinitis, Allergic, SeasonalNCT01500629McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.21